Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aquaprin Cold & Flu is an over-the-counter (OTC) effervescent medication developed for the relief of symptoms associated with the common cold and influenza, such as fever, minor aches, pains, and nasal congestion. The product is built upon the **Aquaprin** platform, which features an FDA-approved effervescent formulation of **aspirin** (acetylsalicylic acid). The effervescent delivery system is designed to enhance the rate of absorption and provide a faster onset of therapeutic action compared to traditional solid oral tablets. In its 'Cold & Flu' iteration, the formulation typically combines the analgesic and antipyretic properties of aspirin with additional active ingredients such as a decongestant (e.g., phenylephrine) and/or an antihistamine (e.g., chlorpheniramine). The intellectual property and commercialization rights for the brand were notably acquired by PharmStar Pharmaceuticals (via a reverse acquisition of PharmStar Incorporated) in 2011 to facilitate fundraising and market expansion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aquaprin Cold & Flu.